methyl 2,5-dimethyloxazole-4-carboxylate | 73537-07-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 2,5-dimethyloxazole-4-carboxylate
• 英文别名: methyl 2,5-dimethyl-1,3-oxazole-4-carboxylate
• CAS: 73537-07-2
• 化学式: C₇H₉NO₃
• 分子量: 155.153
• InChiKey: MCHAPPBWMQBRAI-UHFFFAOYSA-N

物化性质

• 熔点：
  42-44 °C
• 沸点：
  199.0±20.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  methyl 2,5-dimethyloxazole-4-carboxylate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 (2,5-二甲基-1,3-噁唑-4-基)甲醇
  参考文献：
  名称：

  作为选择性过氧化物酶体增殖物激活受体 γ 部分激动剂的一系列新型 2,7-取代-6-四唑基-1,2,3,4-四氢异喹啉衍生物的合成和评价

  摘要：

  合成了一系列新型 7-取代-2-[3-(2-呋喃基)丙烯酰基]-6-四唑基-1,2,3,4-四氢异喹啉衍生物，以阐明过氧化物酶体增殖物激活受体 γ 的结构-活性关系(PPARγ) 部分激动剂活性，并确定更有效且副作用较小的 PPARγ 部分激动剂。合成的衍生物中，四氢异喹啉结构7位带有2-(2,5-二氢吡咯-1-基)-5-甲基恶唑-4-基甲氧基的化合物26v表现出更强的PPARγ激动剂和拮抗剂活性(EC 50 = 6 nM 和 IC 50 = 101 nM) 比之前报道的化合物1值（EC 50 = 13 nM 和 IC 50 = 512 nM）。化合物26v具有非常弱的蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制活性，并且比化合物1 ( C max = 11.4 µg/mL 和曲线下面积 ( AUC ) = 134.7 µg·h/mL ) 显示出更高的口服吸收 ( C max = 11.4

  DOI：

  10.1248/cpb.c20-00841
• 作为产物：
  描述：

  (Z)-methyl 2-acetamido-3-methoxyacrylate 在 碘苯二乙酸 、 三氟化硼乙醚 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 1.5h， 以37%的产率得到methyl 2,5-dimethyloxazole-4-carboxylate
  参考文献：
  名称：

  Synthesis of Oxazoles from Enamides via Phenyliodine Diacetate-Mediated Intramolecular Oxidative Cyclization

  摘要：

  A group of functionalized oxazoles were synthesized in moderate to good yields from enamides via phenyliodine diacetate (PIDA)-mediated intramolecular cyclization. The main advantageous features of the present method include its broad substrate scope and the heavy-metal-free characteristic of the oxidative carbon-oxygen bond formation process.

  DOI：

  10.1021/jo302073e

文献信息

• Total synthesis of siphonazole and its O-methyl derivative, structurally unusual bis-oxazole natural products
  作者：Jörg Linder、Alexander J. Blake、Christopher J. Moody

  DOI：10.1039/b810855b

  日期：——

  The details of the first syntheses of the unusual bis-oxazole natural products siphonazole and its O-methyl derivative are reported. The cinnamyl substituted oxazole was constructed using diazocarbonyl chemistry, whereby the cinnamamide was reacted with the rhodium carbene derived from methyl 2-diazo-3-oxobutanoate to give a β-ketoamide that was cyclodehydrated to the corresponding oxazole-4-ester. Reduction to the corresponding aldehyde was followed by coupling with a zinc reagent derived from methyl 2-iodomethyl-5-methyloxazole-4-carboxylate, also prepared using rhodium carbene chemistry, to give, after oxidation of the resulting secondary alcohol, the desired bis-oxazole ketone. The syntheses were completed by hydrolysis of the ester and coupling of the 2,4-pentadienylamine side chain.

  报道了不寻常的双噁唑天然产物siphonazole及其O-甲基衍生物的首次合成细节。采用重氮羰基化学构建了肉桂基取代的噁唑，将肉桂酰胺与来自甲基2-重氮-3-氧代丁酸酯的铑卡宾反应，生成β-酮酰胺，随后环脱水生成相应的噁唑-4-酯。将其还原为相应的醛后，与来自甲基2-碘甲基-5-甲基噁唑-4-羧酸酯的锌试剂耦合，同样使用铑卡宾化学进行合成，得到的次级醇经过氧化后，得到所需的双噁唑酮。合成通过水解酯和耦合2,4-戊二烯基胺侧链完成。
• PYRIMIDODIAZEPINONE DERIVATIVE
  申请人：Otsubo Nobumasa

  公开号：US20100190775A1

  公开（公告）日：2010-07-29

  The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R 1 and R 2 may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH 2 ) m (wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally substituted pyridinediyl, or C═O, R 3 represents a hydrogen atom, optionally substituted lower alkyl, or the like, and R 4 represents a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof or the like.

  该发明提供了一种由通式(I)表示的嘧啶二氮杂环酮衍生物[其中n代表1或2，Z代表氢原子或类似物，R1和R2可以相同或不同，每个代表氢原子或类似物，A代表键合，(CH2)m(其中m代表1到4的整数)、可选取代的苯基、可选取代的吡啶二基、或C═O，R3代表氢原子、可选取代的较低烷基或类似物，R4代表氢原子或类似物]，或其药学上可接受的盐或类似物。
• RhII-catalyzed cycloadditions of carbomethoxy iodonium ylides
  作者：Christina Batsila、George Kostakis、Lazaros P Hadjiarapoglou

  DOI：10.1016/s0040-4039(02)01260-1

  日期：2002.8

  Carbomethoxy iodonium ylides, generated from methyl acetoacetate and methyl malonate, respectively, are exploited in synthesis of cyclopropanes, cyclopropenes as well as various heterocycles. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Synthesis and Evaluation of a Novel Series of 2,7-Substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonists
  作者：Ko Morishita、Yuma Ito、Kazuya Otake、Kenji Takahashi、Megumi Yamamoto、Tatsuya Kitao、Shin-ichiro Ozawa、Shuichi Hirono、Hiroaki Shirahase

  DOI：10.1248/cpb.c20-00841

  日期：2021.4.1

  A novel series of 7-substituted-2-[3-(2-furyl)acryloyl]-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized to clarify structure–activity relationships for peroxisome proliferator-activated receptor γ (PPARγ) partial agonist activity and identify more efficacious PPARγ partial agonists with minor adverse effects. Among the derivatives synthesized, compound 26v with a 2-(2,5-di

  合成了一系列新型 7-取代-2-[3-(2-呋喃基)丙烯酰基]-6-四唑基-1,2,3,4-四氢异喹啉衍生物，以阐明过氧化物酶体增殖物激活受体 γ 的结构-活性关系(PPARγ) 部分激动剂活性，并确定更有效且副作用较小的 PPARγ 部分激动剂。合成的衍生物中，四氢异喹啉结构7位带有2-(2,5-二氢吡咯-1-基)-5-甲基恶唑-4-基甲氧基的化合物26v表现出更强的PPARγ激动剂和拮抗剂活性(EC 50 = 6 nM 和 IC 50 = 101 nM) 比之前报道的化合物1值（EC 50 = 13 nM 和 IC 50 = 512 nM）。化合物26v具有非常弱的蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制活性，并且比化合物1 ( C max = 11.4 µg/mL 和曲线下面积 ( AUC ) = 134.7 µg·h/mL ) 显示出更高的口服吸收 ( C max = 11.4
• Synthesis of Oxazoles from Enamides via Phenyliodine Diacetate-Mediated Intramolecular Oxidative Cyclization
  作者：Yunhui Zheng、Xuming Li、Chengfeng Ren、Daisy Zhang-Negrerie、Yunfei Du、Kang Zhao

  DOI：10.1021/jo302073e

  日期：2012.11.16

  A group of functionalized oxazoles were synthesized in moderate to good yields from enamides via phenyliodine diacetate (PIDA)-mediated intramolecular cyclization. The main advantageous features of the present method include its broad substrate scope and the heavy-metal-free characteristic of the oxidative carbon-oxygen bond formation process.